格隆汇3月4日｜德国总理默茨：已与美国总统特朗普讨论俄乌冲突，已有超过一百万人丧生。

It was a new-look England as Wiegman is managing the return of several key players from injury, while rewarding those in form. Manchester City's Laura Blindkilde Brown was handed a rare start, while London City Lionesses defender Poppy Pattinson made her debut in the second half. The back four in the starting XI had fewer than 100 caps combined - with captain Leah Williamson earning 65 of them - as Maya Le Tissier was at right-back over Lucy Bronze, while Taylor Hinds started her third game in four matches at left-back. In-form Jess Park was playing out wide, as she has done for Manchester United so impressively this season, rather than in midfield where Wiegman has often used her. It was uncharacteristically experimental from Wiegman considering this was their first competitive fixture since Euro 2025 and it took time to take shape. England had 40 touches in the opposition box and 85% of the possession in the first half, but failed to score from their 15 efforts on goal. The tempo had dropped, Ukraine were defending well and England's hopes of flying out of the blocks had not materialised. "They didn't quite figure it out in the first half. They were a little bit stunned about what to do," ex-England midfielder Fran Kirby told BBC Radio 5 Live Extra. "Ukraine defended really well. They were really tight between the lines and they made it very difficult for England. "They needed to have a little bit more composure in the box instead of crossing it for the sake of crossing it. "The second half showed that they learned from the first half in terms of what wasn't working." With a side stacked full of quality, the two-time European champions responded in the second half. Arsenal striker Alessia Russo netted two goals in four minutes to put England in control, before a double from Georgia Stanway took them out of Ukraine's reach. Wiegman's "clear win" was confirmed when Park also scored twice later on. "I think it took us the first half to break them down. We were still ...

格隆汇3月4日｜德国总理默茨：欧盟不会接受条件差于以往的美国贸易协议。

QUALCOMM (QCOM) built its reputation over the years supplying the chips and connectivity that power modern devices. As artificial intelligence (AI) and 5G reshaped the tech landscape, Qualcomm stood at the center of that shift, benefiting from demand for faster, smarter, and more efficient computing. Yet 2026 has been far less forgiving. Semiconductor stocks have gone through a broad correction, and QCOM has not been spared. The stock is down 19.2% this year, wiping out much of last year’s progress and drifting back toward levels seen several years ago. Weak Q2 guidance in early February, linked to memory shortages and slower smartphone production, added fresh doubts. At the same time, geopolitical tensions and a wider tech sell-off have pressured valuations and crushed the stock’s earlier uptrend. With sentiment fragile and the chart showing clear strain, is this a buy-the-dip opportunity for investors, or a warning sign to remain patient? About QUALCOMM Stock San Diego, California-based QUALCOMM is a fabless semiconductor company with a market cap of $150.5 billion. It shines through its Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI) segments, blending chip innovation with technology licensing and strategic investments. Known for its Snapdragon processors and 5G modems, Qualcomm powers smartphones, smart homes, and connected vehicles. With four decades of expertise, it is expanding intelligent computing through AI, energy-efficient performance, advanced wireless solutions, and its Dragonwing platforms for enterprise and industrial markets. QCOM has had a rough stretch. The stock trades nearly 37.8% below its 52-week high of $205.95, reached last October. Over the past year, shares have slipped about 10%. The pressure has intensified more recently, with the stock down 21% in the last three months. In the first week of January, QCOM was trading above $180. Today, it sits just slightly below $140, essen...

Invesco President & CEO, Andrew Schlossberg and Brookfield Asset Management CEO, Connor Teskey share ways they are delivering personalized investments at scale and where private markets opportunities are playing a bigger role with Bloomberg’s Katie Greifeld at Bloomberg Invest 2026 in New York. (Source: Bloomberg)

Prime Medicine press release ( PRME ): FY GAAP EPS of -$1.35. Revenue of $4.63M. More on Prime Medicine Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond Prime Medicine slips after Q4 updates Seeking Alpha’s Quant Rating on Prime Medicine Historical earnings data for Prime Medicine

Key Points Alibaba’s high-growth days are over, but its e-commerce and cloud businesses are still expanding. Intuitive Machines could evolve into a “one-stop shop” for space logistics services. 10 stocks we like better than Intuitive Machines › It might seem like a risky time to buy more stocks. The S&P 500 looks historically expensive at nearly 30 times earnings, and the intensifying geopolitical conflicts could drive investors from stocks toward more conservative investments. Yet if you can look past those near-term headwinds and plan to hold your stocks for at least a few more years, there are still plenty of bargains that deserve your attention. I believe two of those stocks -- Alibaba (NYSE: BABA) and Intuitive Machines (NASDAQ: LUNR) -- could easily turn a modest $1,000 investment into a lot more money. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Alibaba Alibaba, China's largest e-commerce and cloud infrastructure company, still trades more than 50% below its all-time high from October 2020. Three significant challenges caused that decline. First, China's antitrust regulators fined Alibaba a record amount in 2021. They barred its Chinese marketplaces (Taobao and Tmall) from locking merchants into exclusive deals, using aggressive loss-leading promotions, and expanding through unapproved investments. Those restrictions eroded its defenses against its competitors. Second, the pandemic curbed consumer spending and drove its enterprise customers to rein in their cloud spending. Lastly, the trade conflicts between the U.S. and China drove many U.S. investors away from Chinese equities. Yet Alibaba isn't down for the count. It's expanding its overseas marketplaces (including Lazada in Southeast Asia, Trendyol in Turkey, Daraz in South Asia, and AliExpress for cross-border purchases), as well a...

On February 17, 2026, Knoll Capital Management disclosed a purchase of 473,591 shares of Nuvation Bio (NYSE:NUVB) , an estimated $2.93 million trade based on quarterly average pricing. According to a February 17, 2026 SEC filing , Knoll Capital Management increased its position in Nuvation Bio (NYSE:NUVB) by 473,591 shares. The estimated transaction value is $2.93 million, based on the average closing price within the filing quarter. At quarter end, the fund held 1,498,591 shares, with the value of the position rising by $7.88 million from the previous report, reflecting both the additional purchase and price appreciation. Nuvation Bio is a clinical-stage biotechnology company specializing in the development of innovative oncology therapeutics. The company leverages a robust pipeline of small molecule inhibitors and drug conjugate platforms to address significant gaps in cancer care. With a strategy centered on advancing differentiated therapies for hard-to-treat cancers, Nuvation Bio aims to create a competitive edge through scientific innovation and targeted clinical development. Continue reading

格隆汇3月4日｜德国总理默茨：已告知美国总统特朗普，欧盟应签署并实施与美国的贸易协定。

格隆汇3月4日｜德国总理默茨：在美国最高法院作出裁决后，我们希望在贸易问题上达成公平、持久的解决方案。

格隆汇3月4日｜以色列国防军发言人德夫林在3日的新闻发布会上表示，自对伊朗的军事行动开始以来，以色列国防军空军已向伊朗投掷了4000多枚炸弹，超过了2025年6月以伊两国之间为期12天的军事冲突期间使用的炸弹数量。

巴克莱的外汇与新兴市场宏观策略全球主管Themos Fiotakis在接受采访时表示，债券和股票市场并未将霍尔木兹海峡被封锁数周的情形纳入定价。 “这可能就是为什么市场没有进一步把航道被封锁3到4周的情形完全计入价格，但如果这一风险真的发生，那么我们目前的定价并未充分反映这种情况。” 他说，市场如今“被提醒：欧洲大陆依赖来自地球上最危险地区的能源，这是一个重大脆弱点。” 责任编辑：丁文武

格隆汇3月4日｜德国总理默茨：美国总统特朗普向我保证，美国将坚守驻德承诺。

格隆汇3月4日｜德国总理默茨：美国总统特朗普承认德国在增加国防开支方面的作用。

格隆汇3月4日｜德国总理默茨：已就北约安卡拉峰会与美国总统特朗普进行了交谈。

格隆汇3月4日｜德国总理默茨：军事打击存在风险，需要制定“战后”应对计划。

格隆汇3月4日｜德国总理默茨：希望达成一项永久终止伊朗核计划的协议。

Stocks in Turmoil, but Attractive Setups Emerge (META, GOOGL, AMZN) The Globe and Mail

Key Points Oil prices have surged recently due to the war with Iran. They could continue rising if Iran successfully impedes oil exports from the Persian Gulf. While U.S. producers can ramp up their production, it will take some time. 10 stocks we like better than ConocoPhillips › Crude oil prices are soaring in the aftermath of U.S. and Israeli strikes on Iran. Brent oil, the global benchmark price, is up more than 5% again today, and has risen roughly 15% in the past couple of days. The surge in crude prices has sent oil stocks soaring. ConocoPhillips (NYSE: COP) has popped nearly 8% in the past few days, while Chevron (NYSE: CVX) closed at a record high on Monday at nearly $190 per share. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Here are two things investors need to know about the current state of the oil sector before buying oil stocks. All eyes are currently on the Strait of Hormuz The war with Iran has massive implications for the oil sector. The Middle Eastern country is a founding member of OPEC and produces over 3 million barrels of oil per day. Additionally, roughly 20 million barrels of oil per day pass through the Strait of Hormuz in the Persian Gulf, about 20% of global supplies. Iran has long threatened to close the Strait of Hormuz in retaliation for military action against the country. While the U.S. military is working to prevent its closure, the war is having an impact on the flow of oil out of the region. Supertanker rates surged to record highs after Iran attacked several ships. Additionally, insurance companies have canceled war risk coverage. These surging costs will likely prevent companies from taking the risk of transporting oil out of the region until things calm down. If there's a prolonged period where oil doesn't freely flow out of the Persian Gulf, it could cau...

Key Points Ripple recently rebranded and is leaning into stablecoins following the launch of RLUSD. XRP's core investment thesis could be undermined by RLUSD. Ripple may thrive in 2026, but that success may not translate to gains for XRP holders. 10 stocks we like better than XRP › After rocketing to highs nearing $3.50 last year, XRP (CRYPTO: XRP) has fallen below $1.50 as Bitcoin and the broader crypto market slide. Investors may be wondering if they should jump in and buy the dip. But the current sell-off might not be the real concern for XRP holders; it's possible the dip isn't a dip at all, but a new normal. So, where might XRP be a year from now? Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » To answer that, we have to look at Ripple, the company behind the token, and its pivot toward stablecoins. Ripple is all-in on stablecoins Ripple has spent the past year and change repositioning itself as a stablecoin infrastructure company. Its website now leads with "integrate stablecoin payments into your business." It acquired stablecoin payments company Rail for $200 million. And it launched RLUSD, its own dollar-backed stablecoin, which it's aggressively pushing into the cross-border payments market. This isn't happening in a vacuum. The Genius Act provided stablecoins with real regulatory clarity, and Ripple is building to capitalize on it. RLUSD can function as a bridge asset within Ripple's cross-border payment products. That might sound tangential to what we're discussing -- XRP's value -- but it very much is not. It's critically important because XRP has always been the key bridge asset in Ripple's cross-border payment system. RLUSD's adoption cannibalizes XRP's "market share" within its own ecosystem. Why RLUSD complicates XRP's bull case XRP's investment thesis has always rested on the ide...

Eli Lilly's (LLY 0.73%) big problem is its success in the GLP-1 drug space. Its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs grew sales by 99% and 175%, respectively, in 2025. That's impressive, but Wall Street is perhaps a bit too excited about the stock. Here's why you might want to forget about Eli Lilly and buy GLP-1 laggards Novo Nordisk (NVO 2.73%) and Pfizer (PFE 1.67%) instead. Eli Lilly is the victim of its own success It's hard to complain about a pharmaceutical company that has approved drugs in its portfolio that are growing as quickly as those from Eli Lilly. However, there are a few issues to consider. For starters, those levels of sales growth probably aren't sustainable over the long term. Also, Mounjaro and Zepbound basically accounted for nearly all of Lilly's 45% sales growth in 2025. The most worrying problem, however, is that these two GLP-1 weight loss drugs already account for 56% of the company's top line. When patent protections on these drugs eventually end, there's going to be a huge hole to fill. Meanwhile, Wall Street is extremely excited about the stock, bidding the shares up to the point where the dividend yield is a tiny 0.6% and the price-to-earnings (P/E) ratio is a lofty 44. Other GLP-1 options to consider If you have a value bias or prefer stocks with higher yields, you'll probably want to look at GLP-1 competitors Novo Nordisk and Pfizer. Novo Nordisk was the first to launch a GLP-1 drug, but lost the lead to Eli Lilly because Lilly's drugs seem to be more effective right now. That said, Novo Nordisk was recently first to market with an oral GLP-1 medication, and it continues to invest in its related offerings. Expand NYSE : NVO Novo Nordisk Today's Change ( -2.73 %) $ -1.03 Current Price $ 36.73 Key Data Points Market Cap $127B Day's Range $ 35.85 - $ 36.95 52wk Range $ 35.85 - $ 91.90 Volume 1.4M Avg Vol 23M Gross Margin 80.90 % Dividend Yield 4.57 % Novo Nordisk recently announced the results of a GLP-1 drug tr...

Key Points Sales of Eli Lilly's Mounjaro and Zepbound GLP-1 drugs have been growing rapidly. Novo Nordisk and Pfizer are trailing Lilly, but don't count out these pharma giants just yet. 10 stocks we like better than Eli Lilly › Eli Lilly's (NYSE: LLY) big problem is its success in the GLP-1 drug space. Its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs grew sales by 99% and 175%, respectively, in 2025. That's impressive, but Wall Street is perhaps a bit too excited about the stock. Here's why you might want to forget about Eli Lilly and buy GLP-1 laggards Novo Nordisk (NYSE: NVO) and Pfizer (NYSE: PFE) instead. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Eli Lilly is the victim of its own success It's hard to complain about a pharmaceutical company that has approved drugs in its portfolio that are growing as quickly as those from Eli Lilly. However, there are a few issues to consider. For starters, those levels of sales growth probably aren't sustainable over the long term. Also, Mounjaro and Zepbound basically accounted for nearly all of Lilly's 45% sales growth in 2025. The most worrying problem, however, is that these two GLP-1 weight loss drugs already account for 56% of the company's top line. When patent protections on these drugs eventually end, there's going to be a huge hole to fill. Meanwhile, Wall Street is extremely excited about the stock, bidding the shares up to the point where the dividend yield is a tiny 0.6% and the price-to-earnings (P/E) ratio is a lofty 44. Other GLP-1 options to consider If you have a value bias or prefer stocks with higher yields, you'll probably want to look at GLP-1 competitors Novo Nordisk and Pfizer. Novo Nordisk was the first to launch a GLP-1 drug, but lost the lead to Eli Lilly because Lilly's drugs seem to be more effective right n...

以色列国防军（IDF）在Telegram上表示，袭击了伊朗发展核武器能力的Minzadehei设施群。 IDF称，一群核科学家在该地点秘密运作，研发核武器的关键部件。 此次打击摧毁了伊朗政权发展核武器能力的一个关键部分。 尽管遭受严重损失，伊朗并未停止核武器活动，而是继续推进核武器所需能力的研发。 将基础设施转移到可抵御空袭的地下。 责任编辑：丁文武

The US war in Iran hasn’t changed Brookfield Asset Management ’s plans to build data centers with the Qatar Investment Authority or curbed its appetite for investing in the Middle East, Chief Executive Officer Connor Teskey said. “When something like the past weekend happens, the focus is on our people who are safe, both at Brookfield and our portfolio companies, and then our focuses are on the assets, and those are all performing,” Teskey said in a Bloomberg Television interview Tuesday, Iran’s supreme leader, Ayatollah Ali Khamenei, was killed on Saturday after the US and Israel launched airstrikes in Tehran. The US-Israeli war on Iran has reverberated across the region, and President Donald Trump has said the conflict could last for weeks. Amazon.com Inc.’s cloud unit has warned of prolonged disruptions to its services as the battle intensifies. Drone strikes damaged at least three of its data centers in the region in recent days. When asked if the war impacts Brookfield Asset Management’s $20 billion venture with Qatar’s sovereign wealth fund to invest in artificial-intelligence infrastructure, Teskey said that it does not affect the project and called the Middle East an “incredible” region. “We’re very long-term investors,” he said. The Middle East has “got an increasing presence on the world scene — those are the types of asset classes and geographies that we want to be investing in long term.” Read More: Missiles Seen Over Abu Dhabi Financial Hub Dent Safe Haven Image The New York-based firm is a key player in the AI buildout, which it expects requires roughly $7 trillion of capital investment over the next decade. Brookfield has invested in data-center operators and acquired stakes in power utilities that are benefiting from surging power demand. Brookfield is also collaborating with Gulf sovereign wealth funds on AI ventures, partnering with Kuwait Investment Authority on a $10 billion fund dedicated to AI infrastructure. Teskey became CEO of the asset mana...

格隆汇3月4日｜德国总理默茨：不确定军事打击是否会引发伊朗政府内部变革。

格隆汇3月4日｜德国总理默茨：政权更迭对伊朗和伊朗人民都是好消息。

格隆汇3月4日｜德国总理默茨：伊朗政权应对全球范围内的大量恐怖主义活动负有个人责任。

格隆汇3月4日｜以色列军方对黎巴嫩南部三座城镇发布撤离警告。

在西方制裁削弱其空军力量后，伊朗对导弹和无人机投入巨资。根据美国情报部门2025年初的评估，这个伊斯兰国家此类武器系统库存量位居“中东第一”。 美国和以色列长期以来致力于消除这一威胁，在最近对伊朗的战争中，美以联军打击军事目标的同时，也在攻击其导弹和无人机发射点。 然而，这些系统由于分布广泛、隐蔽性强且往往具备机动性，摧毁难度较大。伊朗军方正利用这些武器袭击以色列、美军中东基地以及波斯湾地区多国的其他目标。尽管大部分伊朗发射物被成功拦截，但仍有一些漏网并造成致命后果。 伊朗制造的“见证者”无人机。 为什么伊朗的导弹和无人机一直是关注焦点？ 数十年来，伊朗一直致力于提升其无人机和导弹的破坏力与射程，其中射程最远的型号已将欧洲东南部纳入打击范围。 外界对伊朗研发核武器的担忧进一步推高了局势风险。假设该国科学家掌握了相关技术要求，弹道导弹将使伊朗具备远距离投送核装置的能力。 伊朗还向中东地区的盟友民兵组织输出导弹、无人机或相关制造技术，包括黎巴嫩真主党和也门胡塞武装。此举增强了这些组织的“防区外”打击能力——即在不直接承受目标区火力的情况下从远距离实施攻击。 他们已使用这些防区外武器袭击以色列及红海船只。胡塞武装曾宣称对2019年沙特石油加工设施遭到的毁灭性袭击负责，而沙特认为罪魁祸首是伊朗。 11月在德黑兰举办的导弹和无人机展览。 在之前的几轮敌对行动中，伊朗曾动用导弹和无人机，包括2020年美军在伊拉克击毙伊斯兰革命卫队指挥官苏莱曼尼后伊朗的报复行动、2024年4月和10月伊朗与以色列交火，以及2025年6月伊朗对以色列和美国的行动。 伊朗低成本的“见证者”无人机在俄乌冲突中也发挥了重要作用。俄罗斯在全面冲突初期进口了伊朗无人机，随后开始大规模生产。据战略与国际研究中心（CSIS）数据，到2025年3月，俄罗斯每周发射1，000架“见证者”以饱和攻击乌克兰的防空系统。事实证明，“见证者”能有效穿透防空网并造成包括人员伤亡在内的损失。 伊朗拥有多少导弹和无人机？ 据以色列军方估计，在本轮冲突开始时，伊朗拥有2，500枚弹道导弹。自战斗爆发以来，伊朗已向邻国发射了数百枚，以色列称他们通过空袭又摧毁了伊朗数百枚导弹。 虽然以色列官方未给出伊朗无人机库存的具体数字，但普遍认为伊朗的无人机数量远超导弹。彭博经济研究的国防负责人Becca Wasser分析称，俄罗斯一天能生产数百...

Anthropic-Palantir Partnership at Risk After Pentagon Ruling The Information